Reyataz and Sustiva Co-Pay Benefit Program
April 16, 2009
Bristol-Myers Squibb is launching a co-pay assistance program in April for eligible new and existing REYATAZ® (atazanavir) and SUSTIVA® (efavirenz) patients who are commercially insured and have high co-pays or co-insurance. We recognize that especially in this economic environment, out-of-pocket costs for HIV medicines may be prohibitive even for patients who have prescription drug benefits. This program reflects Bristol-Myers Squibb's ongoing commitment to helping patients who need our medicines to access them.
The REYATAZ and SUSTIVA Co-pay Benefit Program will allow eligible patients to save up to $200 of co-pay costs monthly, for up to a year. Patients will be responsible for the first $50 of out-of-pocket costs plus any amount over $250. To begin the enrollment process, eligible patients should speak to their healthcare professional to obtain a co-pay benefit card to take to the pharmacy with their prescription.
The co-pay benefit card is not valid in Massachusetts or for prescriptions purchased under Medicaid, Medicare, federal or state programs (including state prescription drug programs, or private indemnity or HMO insurance plans, which reimburse patients for the entire cost of the prescription drugs). First use must take place by December 31, 2009.
This Co-pay Benefit Program is for eligible commercially insured patients only. For patients living with HIV who are uninsured or underinsured, Bristol-Myers Squibb offers other programs to support access to medicines. Bristol-Myers Squibb provides our medicines free of charge to those who qualify through our Access Virology Patient Assistance Program and also participates in the pharmaceutical industry's Together RX Program.
This article was provided by Bristol-Myers Squibb Company.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)